Other Information
−Removed: First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc.
−Removed: Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, between the Company and Melt Pharmaceuticals, Inc.
−Removed: Mutual Termination Agreement, dated October 7, 2022 between ImprimisRx and EyePoint Pharmaceuticals, Inc.
+Added: Loan and Security Agreement dated December 14, 2022, between the Company and B.
+Added: Riley Commercial Capital, LLC
+Added: Credit and Guaranty Agreement, dated March 27, 2023, between the Company and Oaktree Fund Administration, LLC
Certification of Mark L.
13 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, has been formatted in
+Added: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, has been formatted in Inline
+Added: of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
−Removed: November 14, 2022
Executive Officer and Director
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.